Mouse Plasminogen Activator, U

RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene

attachments. One such enzyme, the serine protease urokinase-type plasminogen activator (uPA), converts enzymatically inactive plasminogen into the widely acting protease plasmin, which degrades several extracellular matrix components and also activates

Therapeutic Potential of siRNA-mediated Targeting of Urokinase Plasminogen Activator, Its Receptor, and Matrix Metalloproteinases

is almost catalytic when compared to antisense silencing. Of these targets, the uPAR-uPA system and MMPs holds great promise. Targeting uPA/uPAR may provide additive or synergistic treatment benefits if used in combination with conventional therapeutics

Dissecting the Urokinase Activation Pathway Using Urokinase-Activated Anthrax Toxin

sequence of PrAg with other protease substrate sequences. PrAg-U2 is such a PrAg variant, one that is selectively activated by urokinase plasminogen activator (uPA). The uPA-dependent proteolytic activation of PrAg-U2 on the cell surface is readily detected